These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31288034)

  • 1. Characterization of a Novel Bispecific Antibody With Improved Conformational and Chemical Stability.
    Manikwar P; Mulagapati SHR; Kasturirangan S; Moez K; Rainey GJ; Lobo B
    J Pharm Sci; 2020 Jan; 109(1):220-232. PubMed ID: 31288034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and analysis of scFv-IgG bispecific antibody size variants.
    Cao M; Wang C; Chung WK; Motabar D; Wang J; Christian E; Lin S; Hunter A; Wang X; Liu D
    MAbs; 2018; 10(8):1236-1247. PubMed ID: 30130449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modular IgG-scFv bispecific antibody topology.
    Orcutt KD; Ackerman ME; Cieslewicz M; Quiroz E; Slusarczyk AL; Frangioni JV; Wittrup KD
    Protein Eng Des Sel; 2010 Apr; 23(4):221-8. PubMed ID: 20019028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and production of novel tetravalent bispecific antibodies.
    Coloma MJ; Morrison SL
    Nat Biotechnol; 1997 Feb; 15(2):159-63. PubMed ID: 9035142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
    De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
    J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of biparatopic bispecific antibody possessing tetravalent scFv-Fc capable of binding to ROBO1 expressed in hepatocellular carcinoma cells.
    Watanabe Y; Tanabe A; Hamakubo T; Nagatoishi S; Tsumoto K
    J Biochem; 2021 Oct; 170(2):307-315. PubMed ID: 33844018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of enzymatic reduction on bivalent bispecific antibody fragmentation and loss of product purity upon reoxidation.
    Swope N; Chung WK; Cao M; Motabar D; Liu D; Ahuja S; Handlogten M
    Biotechnol Bioeng; 2020 Apr; 117(4):1063-1071. PubMed ID: 31930476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
    Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
    Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
    Fennell BJ; McDonnell B; Tam AS; Chang L; Steven J; Broadbent ID; Gao H; Kieras E; Alley J; Luxenberg D; Edmonds J; Fitz LJ; Miao W; Whitters MJ; Medley QG; Guo YJ; Darmanin-Sheehan A; Autin B; Shúilleabháin DN; Cummins E; King A; Krebs MR; Grace C; Hickling TP; Boisvert A; Zhong X; McKenna M; Francis C; Olland S; Bloom L; Paulsen J; Somers W; Jensen A; Lin L; Finlay WJ; Cunningham O
    MAbs; 2013; 5(6):882-95. PubMed ID: 23995618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Throughput Generation of Bipod (Fab × scFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity Capture.
    Nesspor TC; Kinealy K; Mazzanti N; Diem MD; Boye K; Hoffman H; Springer C; Sprenkle J; Powers G; Jiang H; La Porte SL; Ganesan R; Singh S; Zwolak A
    Sci Rep; 2020 May; 10(1):7557. PubMed ID: 32372058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.
    Skegro D; Stutz C; Ollier R; Svensson E; Wassmann P; Bourquin F; Monney T; Gn S; Blein S
    J Biol Chem; 2017 Jun; 292(23):9745-9759. PubMed ID: 28450393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermally induced degradation pathways of three different antibody-based drug development candidates.
    Fincke A; Winter J; Bunte T; Olbrich C
    Eur J Pharm Sci; 2014 Oct; 62():148-60. PubMed ID: 24878389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition.
    Yu X; Duval M; Gawron M; Posner MR; Cavacini LA
    J Immunol Res; 2016; 2016():9425172. PubMed ID: 27419146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
    Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J;
    Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
    Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
    J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
    Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
    MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
    Benschop RJ; Chow CK; Tian Y; Nelson J; Barmettler B; Atwell S; Clawson D; Chai Q; Jones B; Fitchett J; Torgerson S; Ji Y; Bina H; Hu N; Ghanem M; Manetta J; Wroblewski VJ; Lu J; Allan BW
    MAbs; 2019; 11(6):1175-1190. PubMed ID: 31181988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
    Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ
    Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.